Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, has announced its participation in two upcoming investor conferences. The company will be present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, in Boston, MA, where management will give a presentation at 8:00 a.m. ET and participate in investor meetings. Additionally, Passage Bio will attend the 15th Annual Wedbush PacGrow Healthcare Conference on August 14, 2024, in New York City, NY, participating in investor meetings.
A live webcast of the Canaccord Genuity conference presentation will be available on the Investors & Media section of Passage Bio's website, with a replay accessible for 30 days following the event. This participation in investor conferences demonstrates Passage Bio's commitment to engaging with the investment community and sharing updates on their progress in developing treatments for neurodegenerative diseases.
Passage Bio (NASDAQ: PASG), un'azienda di biotecnologie in fase clinica, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda sarà presente alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity il 13 agosto 2024, a Boston, MA, dove il management presenterà alle 8:00 a.m. ET e parteciperà a incontri con gli investitori. Inoltre, Passage Bio parteciperà alla 15ª Conferenza Annuale Wedbush PacGrow sulla Salute il 14 agosto 2024, a New York City, NY, partecipando a incontri con gli investitori.
Una webcast in diretta della presentazione alla conferenza Canaccord Genuity sarà disponibile nella sezione Investitori & Media del sito web di Passage Bio, con una registrazione accessibile per 30 giorni dopo l'evento. Questa partecipazione alle conferenze per investitori dimostra l'impegno di Passage Bio nel coinvolgere la comunità degli investitori e nel condividere aggiornamenti sui loro progressi nello sviluppo di trattamenti per le malattie neurodegenerative.
Passage Bio (NASDAQ: PASG), una empresa de medicamentos genéticos en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversores. La empresa estará presente en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity el 13 de agosto de 2024, en Boston, MA, donde la dirección hará una presentación a las 8:00 a.m. ET y participará en reuniones con inversores. Además, Passage Bio asistirá a la 15ª Conferencia Anual de Salud de Wedbush PacGrow el 14 de agosto de 2024, en Nueva York, NY, participando en reuniones con inversores.
Una transmisión en vivo de la presentación de la conferencia de Canaccord Genuity estará disponible en la sección de Inversores y Medios del sitio web de Passage Bio, con una repetición accesible durante 30 días después del evento. Esta participación en conferencias para inversores demuestra el compromiso de Passage Bio con la comunidad de inversión y la compartición de actualizaciones sobre su progreso en el desarrollo de tratamientos para enfermedades neurodegenerativas.
패세지 바이오 (NASDAQ: PASG)는 임상 단계의 유전자 치료 회사로, 두 개의 예정된 투자자 회의에 참가한다고 발표했습니다. 회사는 2024년 8월 13일 매사추세주 보스턴에서 열리는 캐너코드 제뉴이티 제44회 연례 성장 컨퍼런스에 참석하며, 경영진은 오전 8시(동부 표준시)에 발표를 하고 투자자 회의에 참여할 예정입니다. 또한 패세지 바이오는 2024년 8월 14일 뉴욕에서 열리는 웨드버시 팩그로우 헬스케어 제15회 연례 컨퍼런스에도 참석하여 투자자 회의에 참여할 것입니다.
캐너코드 제뉴이티 컨퍼런스 발표의 실시간 웹 캐스트는 패세지 바이오 웹사이트의 투자자 및 미디어 섹션에서 제공되며, 이벤트 후 30일 동안 다시 보기 가능합니다. 이러한 투자자 회의에의 참여는 패세지 바이오가 투자자 커뮤니티와 소통하고, 신경퇴행성 질환 치료 개발의 진행 상황을 공유하는 데 헌신하고 있음을 보여줍니다.
Passage Bio (NASDAQ: PASG), une entreprise de thérapies géniques en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise sera présente à la 44ème Conférence Annuelle sur la Croissance de Canaccord Genuity le 13 août 2024 à Boston, MA, où la direction fera une présentation à 8h00 ET et participera à des réunions avec les investisseurs. De plus, Passage Bio assistera à la 15ème Conférence Annuelle de Santé Wedbush PacGrow le 14 août 2024 à New York, NY, en participant à des réunions d'investisseurs.
Un webinaire en direct de la présentation de la conférence Canaccord Genuity sera disponible dans la section Investisseurs et Médias du site Web de Passage Bio, avec un replay accessible pendant 30 jours après l'événement. Cette participation aux conférences pour investisseurs démontre l'engagement de Passage Bio à interagir avec la communauté des investisseurs et à partager des mises à jour sur leurs progrès dans le développement de traitements pour les maladies neurodégénératives.
Passage Bio (NASDAQ: PASG), ein Unternehmen für genetische Therapien in klinischen Phasen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 13. August 2024 mit einer Präsentation bei der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity in Boston, MA, vertreten sein, wo das Management um 8:00 Uhr ET präsentieren und an Investorenbesprechungen teilnehmen wird. Zusätzlich wird Passage Bio an der 15. jährlichen Wedbush PacGrow Gesundheitskonferenz am 14. August 2024 in New York City, NY, teilnehmen und an Investorenbesprechungen teilnehmen.
Ein Live-Webcast der Präsentation auf der Canaccord Genuity-Konferenz wird im Abschnitt Investoren & Medien auf der Website von Passage Bio verfügbar sein, wobei eine Aufzeichnung für 30 Tage nach der Veranstaltung zugänglich ist. Diese Teilnahme an Investorenkonferenzen zeigt das Engagement von Passage Bio, mit der Investorencommunity in Kontakt zu treten und Updates zu ihren Fortschritten bei der Entwicklung von Behandlungen für neurodegenerative Erkrankungen zu teilen.
- None.
- None.
PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
Canaccord Genuity 44th Annual Growth Conference
Format: Management will participate in a presentation and investor meetings
Date: Tuesday, August 13, 2024
Presentation Time: 8:00 a.m. ET
Location: Boston, MA
15th Annual Wedbush PacGrow Healthcare Conference
Format: Management will participate in investor meetings
Date: Wednesday, August 14, 2024
Location: New York City, NY
A live webcast of the presentation will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When is Passage Bio (PASG) presenting at the Canaccord Genuity Growth Conference?
Which investor conferences is Passage Bio (PASG) attending in August 2024?
How can investors access Passage Bio's (PASG) presentation at the Canaccord Genuity conference?
What type of company is Passage Bio (PASG)?
